[Animal experiment, pharmacokinetic and clinical studies of intraperitoneal therapy with interleukin-2 (n Il-2) in patients with ovarian carcinoma].
OBJECTIVE
In an orthotopic transplantation model using human ovarian cancer xenografts we evaluated antitumor effects of nIL-2 as well as its side effects in a clinical phase I/II study.


METHODS
In patients with advanced ovarian cancer nIL-2 was administered i.p. in escalating doses every two days by means of a Tenckhoff-catheter.


RESULTS
Considerable stimulation of intraperitoneal immune cells was observed without severe toxic side effect WHO grade III/IV.


CONCLUSIONS
Due to pharmacological-pharmacokinetic advantages using the i.p. route nIL-2 was very well tolerated and showed considerable stimulation of local immune cells.
Schröder
W
W
Universitäts-Frauenklinik Aachen, FRG.
Schwuléra
U
U
Lissner
R
R
Bender
H G
HG
D000328:Adult; D000818:Animals; D010478:Chemotherapy, Cancer, Regional Perfusion; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008875:Middle Aged; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D007376:Interleukin-2
Tierexperimentelle, pharmakokinetische und klinische Untersuchungen zur intraperitonealen Therapie mit Interleukin-2 (n IL-2) bei Patientinnen mit Ovarialkarzinom.